APOE and Alzheimer disease: In brief, 92 CN controls (mean age, 75.70 ± 5.45; male, 50.0%), 148 MCI patients (mean age, 74.84 ± 7.23; male, 68.9%), and 69 AD patients (mean age, 74.94 ± 7.61; male, 56.5%) with available baseline CSF ApoE from ADNI-1 cohort were included.